Now available SIMLANDI®

SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for:

• Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA
• Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older
• Psoriatic Arthritis (PsA): Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA 
• Ankylosing Spondylitis (AS): Reducing signs and symptoms in adult patients with active AS
• Crohn’s Disease (CD): Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
• Ulcerative Colitis (UC): Treatment of moderately to severely active ulcerative colitis in adult patients

Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.

• Plaque Psoriasis (Ps): Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
• Hidradenitis Suppurativa (HS): treatment of moderate to severe hidradenitis suppurativa in adult patients
• Uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients 

View full prescribing information.